Trial Profile
A Study to Evaluate Whether Fingolimod Increases CD39-Expressing Regulatory T Cells in Patients with Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Dec 2015
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 29 Dec 2015 New trial record